Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference [url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced new interim data from the ALYFTREKÂ (vanzacaftor/tezacaftor/deutivacaftor) 2 to